GE Aerospace raised its full-year earnings outlook and beat expectations on its top and bottom lines in the second quarter. PepsiCo said its business remained resilient during the second quarter, ...

PepsiCo stock rose after second-quarter earnings per share came in at $2.12 on revenue of $22.7 billion, topping analysts ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

PepsiCo said on Thursday that it was expecting a smaller drop in annual core profit, helped by a rebound in demand for its ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

Large unusual trading volume in Pfizer, Inc. (PFE) put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10 ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

Pfizer's stock was charging 4.5% higher in recent trading, and was sharing the top spot on the S&P 500's gainers list with Fox Corp., after the drug maker provided profit and revenue guidance.